MARKET

ADAG

ADAG

Adagene Inc.
NASDAQ
2.730
+0.090
+3.41%
After Hours: 2.580 -0.15 -5.49% 16:52 04/22 EDT
OPEN
2.570
PREV CLOSE
2.640
HIGH
2.730
LOW
2.570
VOLUME
1.39K
TURNOVER
0
52 WEEK HIGH
4.380
52 WEEK LOW
1.100
MARKET CAP
120.44M
P/E (TTM)
-6.3092
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ADAG last week (0415-0419)?
Weekly Report · 11h ago
Weekly Report: what happened at ADAG last week (0408-0412)?
Weekly Report · 04/15 11:47
Weekly Report: what happened at ADAG last week (0401-0405)?
Weekly Report · 04/08 11:53
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
TipRanks · 04/05 10:30
12 Health Care Stocks Moving In Monday's Intraday Session
Sunshine Biopharma (NASDAQ:SBFM) stock rose 86.3% to $0.11 during Monday's regular session. Xilio Therapeutics stock rose 25.93% and Mesoblast shares moved upwards by 20.95%. Eiger BioPharmaceuticals stock fell 67.8% during the regular session to $1.61.
Benzinga · 04/01 16:31
Weekly Report: what happened at ADAG last week (0325-0329)?
Weekly Report · 04/01 11:50
Adagene Inc. Strikes Deal to Sell Depositary Shares
Adagene, Inc. Has entered into a sales agreement with Leerink Partners LLC to sell American Depositary Shares. The move allows Adagene to potentially raise capital flexibly, depending on market conditions and their operational needs. The company will sell 1.25 ordinary shares in May 2022.
TipRanks · 03/29 19:57
Adagene ADR Non-GAAP EPS of -$0.21, revenue of $18.11M
Seeking Alpha · 03/29 16:47
More
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Webull offers Adagene Inc (ADR) stock information, including NASDAQ: ADAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAG stock methods without spending real money on the virtual paper trading platform.